A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV

Michael T. Yin, Arindam RoyChoudhury, Mariana Bucovsky, Ivelisse Colon, David C. Ferris, Susan Olender, Sanchita Agarwal, Anjali Sharma, Cosmina Zeana, Barry S. Zingman, Elizabeth Shane

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Prevalence of osteoporosis and fracture is increased among older people with HIV. We compared the effects of low (1000 IU) vs moderate (3000 IU) vitamin D3 (VitD) supplementation on areal bone mineral density (aBMD) and volumetric bone mineral density (vBMD) in African American and Hispanic postmenopausal women with HIV on antiretroviral therapy. METHODS: We performed a 12-month prospective, randomized, double-blind, placebo-controlled study with primary outcomes of change in aBMD by dual-energy X-ray absorptiometry (DXA) and secondary outcomes of change in vBMD by quantitative computed tomography and bone turnover markers. An intent-to-treat analysis was performed on 85 randomized subjects (43 low and 42 moderate) for primary DXA outcomes, and complete case analysis was performed for secondary outcomes. RESULTS: Mean age was 56 ± 5 years, median CD4 count was 722 cells/mm, and 74% had HIV RNA ≤ 50 copies/mL. Serum 25-OHD was higher in the moderate than low VitD group at 6 months (33.1 ± 10.3 vs 27.8 ± 8.1 ng/mL, P = 0.03) and 12 months, but parathyroid hormone levels remained similar. Percent change in aBMD, vBMD, and bone turnover markers did not differ between low and moderate VitD groups before or after adjustment for baseline aBMD. CONCLUSIONS: VitD supplementation at 3000 IU daily increased mean total 25-OHD levels in postmenopausal women with HIV, but we did not find evidence of an effect on BMD beyond those observed with 1000 IU daily. Future studies are necessary to determine whether VitD supplementation is beneficial in this patient population, and if so, what dose is optimal for skeletal health.

Original languageEnglish (US)
Pages (from-to)342-349
Number of pages8
JournalJournal of acquired immune deficiency syndromes (1999)
Volume80
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Cholecalciferol
Bone Density
Randomized Controlled Trials
Placebos
HIV
Bone Remodeling
Photon Absorptiometry
CD4 Lymphocyte Count
Parathyroid Hormone
Hispanic Americans
African Americans
Osteoporosis
Tomography
RNA
Bone and Bones
Health
Serum
Population

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV. / Yin, Michael T.; RoyChoudhury, Arindam; Bucovsky, Mariana; Colon, Ivelisse; Ferris, David C.; Olender, Susan; Agarwal, Sanchita; Sharma, Anjali; Zeana, Cosmina; Zingman, Barry S.; Shane, Elizabeth.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 80, No. 3, 01.03.2019, p. 342-349.

Research output: Contribution to journalArticle

Yin, Michael T. ; RoyChoudhury, Arindam ; Bucovsky, Mariana ; Colon, Ivelisse ; Ferris, David C. ; Olender, Susan ; Agarwal, Sanchita ; Sharma, Anjali ; Zeana, Cosmina ; Zingman, Barry S. ; Shane, Elizabeth. / A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV. In: Journal of acquired immune deficiency syndromes (1999). 2019 ; Vol. 80, No. 3. pp. 342-349.
@article{eb20cc40b4fd4b89abeb0bf1bac366a6,
title = "A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV",
abstract = "BACKGROUND: Prevalence of osteoporosis and fracture is increased among older people with HIV. We compared the effects of low (1000 IU) vs moderate (3000 IU) vitamin D3 (VitD) supplementation on areal bone mineral density (aBMD) and volumetric bone mineral density (vBMD) in African American and Hispanic postmenopausal women with HIV on antiretroviral therapy. METHODS: We performed a 12-month prospective, randomized, double-blind, placebo-controlled study with primary outcomes of change in aBMD by dual-energy X-ray absorptiometry (DXA) and secondary outcomes of change in vBMD by quantitative computed tomography and bone turnover markers. An intent-to-treat analysis was performed on 85 randomized subjects (43 low and 42 moderate) for primary DXA outcomes, and complete case analysis was performed for secondary outcomes. RESULTS: Mean age was 56 ± 5 years, median CD4 count was 722 cells/mm, and 74{\%} had HIV RNA ≤ 50 copies/mL. Serum 25-OHD was higher in the moderate than low VitD group at 6 months (33.1 ± 10.3 vs 27.8 ± 8.1 ng/mL, P = 0.03) and 12 months, but parathyroid hormone levels remained similar. Percent change in aBMD, vBMD, and bone turnover markers did not differ between low and moderate VitD groups before or after adjustment for baseline aBMD. CONCLUSIONS: VitD supplementation at 3000 IU daily increased mean total 25-OHD levels in postmenopausal women with HIV, but we did not find evidence of an effect on BMD beyond those observed with 1000 IU daily. Future studies are necessary to determine whether VitD supplementation is beneficial in this patient population, and if so, what dose is optimal for skeletal health.",
author = "Yin, {Michael T.} and Arindam RoyChoudhury and Mariana Bucovsky and Ivelisse Colon and Ferris, {David C.} and Susan Olender and Sanchita Agarwal and Anjali Sharma and Cosmina Zeana and Zingman, {Barry S.} and Elizabeth Shane",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/QAI.0000000000001929",
language = "English (US)",
volume = "80",
pages = "342--349",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV

AU - Yin, Michael T.

AU - RoyChoudhury, Arindam

AU - Bucovsky, Mariana

AU - Colon, Ivelisse

AU - Ferris, David C.

AU - Olender, Susan

AU - Agarwal, Sanchita

AU - Sharma, Anjali

AU - Zeana, Cosmina

AU - Zingman, Barry S.

AU - Shane, Elizabeth

PY - 2019/3/1

Y1 - 2019/3/1

N2 - BACKGROUND: Prevalence of osteoporosis and fracture is increased among older people with HIV. We compared the effects of low (1000 IU) vs moderate (3000 IU) vitamin D3 (VitD) supplementation on areal bone mineral density (aBMD) and volumetric bone mineral density (vBMD) in African American and Hispanic postmenopausal women with HIV on antiretroviral therapy. METHODS: We performed a 12-month prospective, randomized, double-blind, placebo-controlled study with primary outcomes of change in aBMD by dual-energy X-ray absorptiometry (DXA) and secondary outcomes of change in vBMD by quantitative computed tomography and bone turnover markers. An intent-to-treat analysis was performed on 85 randomized subjects (43 low and 42 moderate) for primary DXA outcomes, and complete case analysis was performed for secondary outcomes. RESULTS: Mean age was 56 ± 5 years, median CD4 count was 722 cells/mm, and 74% had HIV RNA ≤ 50 copies/mL. Serum 25-OHD was higher in the moderate than low VitD group at 6 months (33.1 ± 10.3 vs 27.8 ± 8.1 ng/mL, P = 0.03) and 12 months, but parathyroid hormone levels remained similar. Percent change in aBMD, vBMD, and bone turnover markers did not differ between low and moderate VitD groups before or after adjustment for baseline aBMD. CONCLUSIONS: VitD supplementation at 3000 IU daily increased mean total 25-OHD levels in postmenopausal women with HIV, but we did not find evidence of an effect on BMD beyond those observed with 1000 IU daily. Future studies are necessary to determine whether VitD supplementation is beneficial in this patient population, and if so, what dose is optimal for skeletal health.

AB - BACKGROUND: Prevalence of osteoporosis and fracture is increased among older people with HIV. We compared the effects of low (1000 IU) vs moderate (3000 IU) vitamin D3 (VitD) supplementation on areal bone mineral density (aBMD) and volumetric bone mineral density (vBMD) in African American and Hispanic postmenopausal women with HIV on antiretroviral therapy. METHODS: We performed a 12-month prospective, randomized, double-blind, placebo-controlled study with primary outcomes of change in aBMD by dual-energy X-ray absorptiometry (DXA) and secondary outcomes of change in vBMD by quantitative computed tomography and bone turnover markers. An intent-to-treat analysis was performed on 85 randomized subjects (43 low and 42 moderate) for primary DXA outcomes, and complete case analysis was performed for secondary outcomes. RESULTS: Mean age was 56 ± 5 years, median CD4 count was 722 cells/mm, and 74% had HIV RNA ≤ 50 copies/mL. Serum 25-OHD was higher in the moderate than low VitD group at 6 months (33.1 ± 10.3 vs 27.8 ± 8.1 ng/mL, P = 0.03) and 12 months, but parathyroid hormone levels remained similar. Percent change in aBMD, vBMD, and bone turnover markers did not differ between low and moderate VitD groups before or after adjustment for baseline aBMD. CONCLUSIONS: VitD supplementation at 3000 IU daily increased mean total 25-OHD levels in postmenopausal women with HIV, but we did not find evidence of an effect on BMD beyond those observed with 1000 IU daily. Future studies are necessary to determine whether VitD supplementation is beneficial in this patient population, and if so, what dose is optimal for skeletal health.

UR - http://www.scopus.com/inward/record.url?scp=85061511046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061511046&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001929

DO - 10.1097/QAI.0000000000001929

M3 - Article

VL - 80

SP - 342

EP - 349

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -